Enavate Sciences GP, LLC holds a concentrated book of 7 stocks worth $351.5M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they trimmed Immunome Inc. Their largest long position is Sionna Therapeutics Inc at 28% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1953107/holdings"
Use Arkolith to show Enavate Sciences GP, LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
93% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
No buys this quarter.
Other tracked managers holding the same core names as Enavate Sciences GP, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| FMR LLC | 7 / 7 | $658.3M |
| BlackRock, Inc. | 7 / 7 | $371.8M |
| VANGUARD CAPITAL MANAGEMENT LLC | 7 / 7 | $222.9M |
| STATE STREET CORP | 7 / 7 | $221.6M |
| GEODE CAPITAL MANAGEMENT, LLC | 7 / 7 | $118.8M |
| MORGAN STANLEY | 7 / 7 | $76.6M |
| GOLDMAN SACHS GROUP INC | 7 / 7 | $57.3M |
| UBS Group AG | 7 / 7 | $37.8M |
Ranked by how many of Enavate Sciences GP, LLC's top 7 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.